Merck KGaA, Darmstadt, Germany, Licenses Four Oncology Research and Development Programs from Vertex and Becomes a Leader in DNA Damage and Repair
Merck KGaA, Darmstadt, Germany | January 11, 2017
Merck KGaA, Darmstadt, Germany, a leading science and technology company which operates its biopharmaceutical business in the US and Canada as EMD Serono, today announced that it has entered into a licensing agreement with Vertex Pharmaceuticals Incorporated, Boston, USA, for the worldwide development and commercialization of four promising research and development programs that represent novel approaches to the treatment of
cancer.